10% of the isolates sequenced were new STs whilst only 1% of the isolates typed gave rise to new serotypes. Amongst the 14 serotypes each accounting for at least 1% of IPD cases post-PCV7 (Table 1, Part B), there were significant increasing trends in http://www.selleckchem.com/products/XL184.html serotype 19A and 22F IPD, at rates of 40% and 34% per year, respectively, and decreasing trends for serotypes 1 and 20,

at rates of 29% and 36% per year, respectively. Eleven STs accounted for more than 1% of all STs reported in IPD post-PCV7. ST306 decreased significantly at a rate of 37% per year, comparable with the decrease in serotype 1. ST199 and ST433 both exhibited significant increases post-PCV7 with 25% and 51% increases per year, respectively. ST199 was principally associated with serotype 19A and, to a lesser extent, 15B whilst

PF-06463922 in vitro ST433 was almost universally associated with serotype 22F. Serotype 20 was principally associated with ST235. Associations between serotypes and STs in the period prior to PCV7 use are shown in Table 3. PCV7 serotypes were associated with 166 STs, however only 12 STs (9, 36, 113, 124, 138, 156, 162, 176, 205, 206, 246, 311) account for the vast majority (74.3%) of the IPD cases. PCV7 serotypes, associated with these 12 STs (labelled PCV7-HF PCV7-ST), were responsible for 779 IPD cases. Another 269 cases were caused by PCV7 serotypes associated with the remaining 154 STs (labelled PCV7-LF PCV7-ST). Regarding NVT serotypes associated with the 166 STs linked to PCV7, 25 different serotypes were responsible for 708 IPD cases, of which only 25 were linked with HF PCV7-STs. The other 683 were associated with the remaining 154 low frequency STs (cross-classification of PCV7-ST serotypes and LF PCV7-ST). The 25 PCV7-ST serotypes had associations (353 cases) with 151 STs not directly associated with PCV7 (cross-classification

Vasopressin Receptor of PCV7 ST serotypes and NonPCV7-ST). Finally these 151 NonPCV7-STs were associated with 22 NonPCV7-ST serotypes (145 cases) with no direct link with any ST linked to PCV7. Trends in the distribution of groups of serotypes and STs are presented in Fig. 2 and Fig. 3, respectively. Both show a relatively stable distribution in the pre-PCV7 period. The serotype distribution has changed in favour of those serotypes which were associated with STs shown to have had an association with serotypes in PCV7–the PCV7-ST serotypes. Before 2006/07, these serotypes formed ∼40% of all serotypes but formed 80% in 2009/10. The NonPCV7-ST serotypes formed 6% of serotypes prior to 2006/07, rising to 8% in 2008/09 and 11% in 2009/10. The ratio of the percentage of NonPCV7-ST serotypes to the percentage of PCV7-ST serotypes has remained relatively constant over the whole period. The ST distribution did not change as dramatically but the 12 HF PCV7-STs decreased while the remaining LF PCV7-STs and STs not associated with PCV7 increased by about 10% each. New post-PCV7 STs accounted for ∼10% of STs in 2009/10.